Robert L. Copeland to Male
This is a "connection" page, showing publications Robert L. Copeland has written about Male.
Connection Strength
0.367
-
Kanaan Y, Copeland RL. The link between vitamin D and prostate cancer. Nat Rev Cancer. 2022 08; 22(8):435.
Score: 0.059
-
Copeland RL, Beyene D, Apprey V, Daremipouran MR, Naab TJ, Kassim OO, Kanaan YM. DHPLC Elution Patterns of VDR PCR Products Can Predict Prostate Cancer Susceptibility in African American Men. Cancer Genomics Proteomics. 2017 Nov-Dec; 14(6):461-467.
Score: 0.043
-
Bamji ZD, Washington KN, Akinboye E, Bakare O, Kanaan YM, Copeland RL. Apoptotic Effects of Novel Dithiocarbamate Analogs of Emetine in Prostate Cancer Cell Lines. Anticancer Res. 2015 Sep; 35(9):4723-32.
Score: 0.037
-
Beyene D, Daremipouran M, Apprey V, Williams R, Ricks-Santi L, Kassim OO, Naab TJ, Kanaan YM, Copeland RL. Use of tanning potential as a predictor for prostate cancer risk in African-American men. In Vivo. 2014 Nov-Dec; 28(6):1181-7.
Score: 0.035
-
Kanaan YM, White DF, Das JR, Berhe S, Bakare O, Kenguele H, Beyene D, Zhou Y, Day AA, Copeland RL. Cytotoxic effects of N-(3-chloro-1,4-dioxo 1,4-dihydro-naphthalen-2-yl)-benzamide on androgen-dependent and -independent prostate cancer cell lines. Anticancer Res. 2010 Feb; 30(2):519-27.
Score: 0.025
-
Copeland RL, Das JR, Bakare O, Enwerem NM, Berhe S, Hillaire K, White D, Beyene D, Kassim OO, Kanaan YM. Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines. Anticancer Res. 2007 May-Jun; 27(3B):1537-46.
Score: 0.021
-
Mitropoulos A, Goodwill S, Copeland R, Klonizakis M. The relationship between physical activity and severity of COVID-19 symptoms in non-hospitalized individuals. Eur J Public Health. 2022 10 03; 32(5):794-798.
Score: 0.015
-
Beyene DA, Daremipouran MR, Apprey V, Naab T, Kassim OO, Copeland RL, Kanaan YM. The Association Between the Genetic VDR SNP c.907+75C>T and Prostate Cancer Risk Is Modified by Tanning Potential. Cancer Genomics Proteomics. 2020 Nov-Dec; 17(6):739-745.
Score: 0.013
-
Daremipouran MR, Beyene D, Apprey V, Naab TJ, Kassim OO, Copeland RL, Kanaan YM. The Association of a Novel Identified VDR SNP With Prostate Cancer in African American Men. Cancer Genomics Proteomics. 2019 Jul-Aug; 16(4):245-255.
Score: 0.012
-
Moses-Fynn E, Tang W, Beyene D, Apprey V, Copeland R, Kanaan Y, Kwabi-Addo B. Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men. PLoS One. 2018; 13(9):e0203322.
Score: 0.011
-
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 05; 19(5):649-659.
Score: 0.011
-
Drew AE, Moradei O, Jacques SL, Rioux N, Boriack-Sjodin AP, Allain C, Scott MP, Jin L, Raimondi A, Handler JL, Ott HM, Kruger RG, McCabe MT, Sneeringer C, Riera T, Shapiro G, Waters NJ, Mitchell LH, Duncan KW, Moyer MP, Copeland RA, Smith J, Chesworth R, Ribich SA. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Sci Rep. 2017 12 21; 7(1):17993.
Score: 0.011
-
Akinboye ES, Bamji ZD, Kwabi-Addo B, Ejeh D, Copeland RL, Denmeade SR, Bakare O. Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. Bioorg Med Chem. 2015 Sep 01; 23(17):5839-45.
Score: 0.009
-
Winchester D, Ricks-Santi L, Mason T, Abbas M, Copeland RL, Beyene D, Jingwi EY, Dunston GM, Kanaan YM. SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients. Anticancer Res. 2015 Jul; 35(7):3811-9.
Score: 0.009
-
Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun; 11(6):432-7.
Score: 0.009
-
Kassim OO, Copeland RL, Kenguele HM, Nekhai S, Ako-Nai KA, Kanaan YM. Antiproliferative activities of Fagara xanthoxyloides and Pseudocedrela kotschyi against prostate cancer cell lines. Anticancer Res. 2015 Mar; 35(3):1453-8.
Score: 0.009
-
Jingwi EY, Abbas M, Ricks-Santi L, Winchester D, Beyene D, Day A, Naab TJ, Kassim OO, Dunston GM, Copeland RL, Kanaan YM. Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men. Anticancer Res. 2015 Mar; 35(3):1549-58.
Score: 0.009
-
Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Waters NJ, Smith JJ, Porter-Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Uenaka T, Pollock RM, Kuntz KW, Yokoi A, Keilhack H. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014 Apr; 13(4):842-54.
Score: 0.008
-
Kaleem MA, Ramsahai S, Del Fierro K, Rasul S, Onumah C, Lerebours V, Gajjala J, Copeland RA, Jones LS. Ocular findings in human immunodeficiency virus patients in Washington, DC. Int Ophthalmol. 2012 Apr; 32(2):145-51.
Score: 0.007
-
Brandy Y, Ononiwu I, Adedeji D, Williams V, Mouamba C, Kanaan Y, Copeland RL, Wright DA, Butcher RJ, Denmeade SR, Bakare O. Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines. Invest New Drugs. 2012 Aug; 30(4):1709-14.
Score: 0.007
-
Tizabi Y, Bai L, Copeland RL, Taylor RE. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol. 2007 Sep-Oct; 42(5):413-6.
Score: 0.005
-
Tizabi Y, Copeland RL, Louis VA, Taylor RE. Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol Clin Exp Res. 2002 Mar; 26(3):394-9.
Score: 0.004